Gevokizumab Antibody is a research-grade biosimilar monoclonal antibody targeting Interleukin-1 beta. It is a humanized IgG2-kappa antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% as determined by SDS-PAGE. For research use only.
Interleukin-1 beta (Interleukin-1 beta,IL1B,Catabolin,IL1F2,IL-1 beta) is a ~30 kDa protein. Potent pro-inflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells. Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6.
Product Name:
Gevokizumab Antibody
SKU:
GXBS00003
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
Interleukin-1 beta
Isotype:
IgG2-kappa
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FACS, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
XOMA 052, 1129435-60-4
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
